Dual Allosteric Inhibition of SHP2 Phosphatase
Abstract
SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival. Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2. SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small molecule inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2. In this report, we describe further screening strategies that enabled the identification of a second, distinct small molecule allosteric site. SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme. X-ray crystallography revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site—a cleft formed at the interface of the N-terminal SH2 and PTP domains. Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochemical inhibition, and subsequent MAPK pathway modulation. Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was observed in KYSE-520 cancer cells. Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochemical inhibition experiments and X-ray crystallography. Combining an allosteric sitemore »
- Authors:
-
more »
- Novartis Inst. for Biomedical Research, Cambridge, MA (United States)
- Harvard Medical School, Boston, MA (United States)
- Publication Date:
- Research Org.:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Org.:
- USDOE Office of Science (SC)
- OSTI Identifier:
- 1435825
- Grant/Contract Number:
- AC02–06CH11357
- Resource Type:
- Journal Article: Accepted Manuscript
- Journal Name:
- ACS Chemical Biology
- Additional Journal Information:
- Journal Volume: 13; Journal Issue: 3; Journal ID: ISSN 1554-8929
- Publisher:
- American Chemical Society (ACS)
- Country of Publication:
- United States
- Language:
- ENGLISH
- Subject:
- 37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY; 59 BASIC BIOLOGICAL SCIENCES; Peptides and proteins; Small molecules; Inhibitors; Inhibition; Screening assays
Citation Formats
Fodor, Michelle, Price, Edmund, Wang, Ping, Lu, Hengyu, Argintaru, Andreea, Chen, Zhouliang, Glick, Meir, Hao, Huai-Xiang, Kato, Mitsunori, Koenig, Robert, LaRochelle, Jonathan R., Liu, Gang, McNeill, Eric, Majumdar, Dyuti, Nishiguchi, Gisele A., Perez, Lawrence B., Paris, Gregory, Quinn, Christopher M., Ramsey, Timothy, Sendzik, Martin, Shultz, Michael David, Williams, Sarah L., Stams, Travis, Blacklow, Stephen C., Acker, Michael G., and LaMarche, Matthew J. Dual Allosteric Inhibition of SHP2 Phosphatase. United States: N. p., 2018.
Web. doi:10.1021/acschembio.7b00980.
Fodor, Michelle, Price, Edmund, Wang, Ping, Lu, Hengyu, Argintaru, Andreea, Chen, Zhouliang, Glick, Meir, Hao, Huai-Xiang, Kato, Mitsunori, Koenig, Robert, LaRochelle, Jonathan R., Liu, Gang, McNeill, Eric, Majumdar, Dyuti, Nishiguchi, Gisele A., Perez, Lawrence B., Paris, Gregory, Quinn, Christopher M., Ramsey, Timothy, Sendzik, Martin, Shultz, Michael David, Williams, Sarah L., Stams, Travis, Blacklow, Stephen C., Acker, Michael G., & LaMarche, Matthew J. Dual Allosteric Inhibition of SHP2 Phosphatase. United States. https://doi.org/10.1021/acschembio.7b00980
Fodor, Michelle, Price, Edmund, Wang, Ping, Lu, Hengyu, Argintaru, Andreea, Chen, Zhouliang, Glick, Meir, Hao, Huai-Xiang, Kato, Mitsunori, Koenig, Robert, LaRochelle, Jonathan R., Liu, Gang, McNeill, Eric, Majumdar, Dyuti, Nishiguchi, Gisele A., Perez, Lawrence B., Paris, Gregory, Quinn, Christopher M., Ramsey, Timothy, Sendzik, Martin, Shultz, Michael David, Williams, Sarah L., Stams, Travis, Blacklow, Stephen C., Acker, Michael G., and LaMarche, Matthew J. 2018.
"Dual Allosteric Inhibition of SHP2 Phosphatase". United States. https://doi.org/10.1021/acschembio.7b00980. https://www.osti.gov/servlets/purl/1435825.
@article{osti_1435825,
title = {Dual Allosteric Inhibition of SHP2 Phosphatase},
author = {Fodor, Michelle and Price, Edmund and Wang, Ping and Lu, Hengyu and Argintaru, Andreea and Chen, Zhouliang and Glick, Meir and Hao, Huai-Xiang and Kato, Mitsunori and Koenig, Robert and LaRochelle, Jonathan R. and Liu, Gang and McNeill, Eric and Majumdar, Dyuti and Nishiguchi, Gisele A. and Perez, Lawrence B. and Paris, Gregory and Quinn, Christopher M. and Ramsey, Timothy and Sendzik, Martin and Shultz, Michael David and Williams, Sarah L. and Stams, Travis and Blacklow, Stephen C. and Acker, Michael G. and LaMarche, Matthew J.},
abstractNote = {SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival. Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2. SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small molecule inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2. In this report, we describe further screening strategies that enabled the identification of a second, distinct small molecule allosteric site. SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme. X-ray crystallography revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site—a cleft formed at the interface of the N-terminal SH2 and PTP domains. Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochemical inhibition, and subsequent MAPK pathway modulation. Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was observed in KYSE-520 cancer cells. Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochemical inhibition experiments and X-ray crystallography. Combining an allosteric site 1 inhibitor with an allosteric site 2 inhibitor led to enhanced pharmacological pathway inhibition in cells. This work illustrates a rare example of dual allosteric targeted protein inhibition, demonstrates screening methodology and tactics to identify allosteric inhibitors, and enables further interrogation of SHP2 in cancer and related pathologies.},
doi = {10.1021/acschembio.7b00980},
url = {https://www.osti.gov/biblio/1435825},
journal = {ACS Chemical Biology},
issn = {1554-8929},
number = 3,
volume = 13,
place = {United States},
year = {Fri Jan 05 00:00:00 EST 2018},
month = {Fri Jan 05 00:00:00 EST 2018}
}
Web of Science
Figures / Tables:
Works referenced in this record:
Crystal Structure of the Tyrosine Phosphatase SHP-2
journal, February 1998
- Hof, Peter; Pluskey, Scott; Dhe-Paganon, Sirano
- Cell, Vol. 92, Issue 4
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
journal, March 1998
- Barford, David; Neel, Benjamin G.
- Structure, Vol. 6, Issue 3
Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains
journal, February 1995
- Pluskey, Scott; Wandless, Thomas J.; Walsh, Christopher T.
- Journal of Biological Chemistry, Vol. 270, Issue 7
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis
journal, June 2014
- Wang, Hsueh-Chun; Chiang, Wei-Fan; Huang, Hsin-Hsiu
- BMC Cancer, Vol. 14, Issue 1
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
journal, November 2001
- Tartaglia, Marco; Mehler, Ernest L.; Goldberg, Rosalie
- Nature Genetics, Vol. 29, Issue 4
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
journal, April 2003
- Tartaglia, Marco; Niemeyer, Charlotte M.; Fragale, Alessandra
- Nature Genetics, Vol. 34, Issue 2
The tyrosine phosphatase Shp2 (PTPN11) in cancer
journal, February 2008
- Chan, Gordon; Kalaitzidis, Demetrios; Neel, Benjamin G.
- Cancer and Metastasis Reviews, Vol. 27, Issue 2
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors
journal, January 2008
- Miyamoto, D.; Miyamoto, M.; Takahashi, A.
- Oncogene, Vol. 27, Issue 25
Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2
journal, April 2016
- LaRochelle, Jonathan R.; Fodor, Michelle; Xu, Xiang
- Biochemistry, Vol. 55, Issue 15
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
journal, October 2006
- Chan, Rebecca J.; Feng, Gen-Sheng
- Blood, Vol. 109, Issue 3
Protein tyrosine phosphatase function: the substrate perspective
journal, January 2007
- Tiganis, Tony; Bennett, Anton M.
- Biochemical Journal, Vol. 402, Issue 1
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
journal, November 2015
- Bunda, Severa; Burrell, Kelly; Heir, Pardeep
- Nature Communications, Vol. 6, Issue 1
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
journal, December 2014
- Li, J.; Jie, H. -B.; Lei, Y.
- Cancer Research, Vol. 75, Issue 3
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
journal, March 2017
- Hui, Enfu; Cheung, Jeanne; Zhu, Jing
- Science, Vol. 355, Issue 6332
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
journal, June 2012
- Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.
- New England Journal of Medicine, Vol. 366, Issue 26
Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew.
journal, December 1992
- Freeman, R. M.; Plutzky, J.; Neel, B. G.
- Proceedings of the National Academy of Sciences, Vol. 89, Issue 23
Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention
journal, August 2014
- Butterworth, Sam; Overduin, Michael; Barr, Alastair J.
- Future Medicinal Chemistry, Vol. 6, Issue 12
Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
journal, June 2010
- M. Scott, Latanya; R. Lawrence, Harshani; M. Sebti, Said
- Current Pharmaceutical Design, Vol. 16, Issue 16
Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
journal, February 2010
- Zhang, Xian; He, Yantao; Liu, Sijiu
- Journal of Medicinal Chemistry, Vol. 53, Issue 6
Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
journal, July 2014
- Zeng, Li-Fan; Zhang, Ruo-Yu; Yu, Zhi-Hong
- Journal of Medicinal Chemistry, Vol. 57, Issue 15
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction
journal, January 2014
- Gilmartin, Aidan G.; Faitg, Thomas H.; Richter, Mark
- Nature Chemical Biology, Vol. 10, Issue 3
Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases
journal, June 2015
- Chio, Cynthia M.; Yu, Xiaoling; Bishop, Anthony C.
- Bioorganic & Medicinal Chemistry, Vol. 23, Issue 12
Selective Detection of Allosteric Phosphatase Inhibitors
journal, April 2013
- Schneider, Ralf; Beumer, Claudia; Simard, Jeffrey R.
- Journal of the American Chemical Society, Vol. 135, Issue 18
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
journal, June 2016
- Chen, Ying-Nan P.; LaMarche, Matthew J.; Chan, Ho Man
- Nature, Vol. 535, Issue 7610
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
journal, July 2016
- Garcia Fortanet, Jorge; Chen, Christine Hiu-Tung; Chen, Ying-Nan P.
- Journal of Medicinal Chemistry, Vol. 59, Issue 17
Identifying and Characterizing Binding Sites and Assessing Druggability
journal, January 2009
- Halgren, Thomas A.
- Journal of Chemical Information and Modeling, Vol. 49, Issue 2
New Method for Fast and Accurate Binding-site Identification and Analysis
journal, February 2007
- Halgren, Tom
- Chemical Biology & Drug Design, Vol. 69, Issue 2
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2
journal, December 2017
- LaRochelle, Jonathan R.; Fodor, Michelle; Ellegast, Jana M.
- Bioorganic & Medicinal Chemistry, Vol. 25, Issue 24
Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment
journal, December 2017
- Xie, Jingjing; Si, Xiaojia; Gu, Shoulai
- Journal of Medicinal Chemistry, Vol. 60, Issue 24
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
journal, January 2009
- Jeffrey Conn, P.; Christopoulos, Arthur; Lindsley, Craig W.
- Nature Reviews Drug Discovery, Vol. 8, Issue 1
Minireview: Not Picking Pockets: Nuclear Receptor Alternate-Site Modulators (NRAMs)
journal, April 2010
- Moore, Terry W.; Mayne, Christopher G.; Katzenellenbogen, John A.
- Molecular Endocrinology, Vol. 24, Issue 4
The extraordinary ligand binding properties of human serum albumin
journal, December 2005
- Fasano, Mauro; Curry, Stephen; Terreno, Enzo
- IUBMB Life (International Union of Biochemistry and Molecular Biology: Life), Vol. 57, Issue 12
Simultaneous Binding of Two Different Drugs in the Binding Pocket of the Human Multidrug Resistance P-glycoprotein
journal, October 2003
- Loo, Tip W.; Bartlett, M. Claire; Clarke, David M.
- Journal of Biological Chemistry, Vol. 278, Issue 41
Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein
journal, July 2004
- Schumacher, Maria A.; Miller, Marshall C.; Brennan, Richard G.
- The EMBO Journal, Vol. 23, Issue 15
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
journal, March 2017
- Wylie, Andrew A.; Schoepfer, Joseph; Jahnke, Wolfgang
- Nature, Vol. 543, Issue 7647
ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia
journal, December 2014
- Wylie, Andrew; Schoepfer, Joseph; Berellini, Giuliano
- Blood, Vol. 124, Issue 21
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
journal, March 2013
- Madhavi Sastry, G.; Adzhigirey, Matvey; Day, Tyler
- Journal of Computer-Aided Molecular Design, Vol. 27, Issue 3
XDS
journal, January 2010
- Kabsch, Wolfgang
- Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2
Features and development of Coot
journal, March 2010
- Emsley, P.; Lohkamp, B.; Scott, W. G.
- Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 4
Works referencing / citing this record:
Exploring the effect of E76K mutation on SHP2 cause gain‐of‐function activity by a molecular dynamics study
journal, August 2018
- Li, Wei‐Ya; Wei, Hui‐Yu; Sun, Ying‐Zhan
- Journal of Cellular Biochemistry, Vol. 119, Issue 12
Synthesis, activity evaluation, and pro-apoptotic properties of novel 1,2,4-triazol-3-amine derivatives as potent anti-lung cancer agents
journal, January 2019
- Sun, Xian-yu; Zhong, Chun-yan; Qiu, Qing-qing
- Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Issue 1
Design, Synthesis, and In Vitro Activity of Pyrazine Compounds
journal, December 2019
- Parsonidis, Panagiotis; Shaik, Mahammad; Serafeim, Athanasia Panagiota
- Molecules, Vol. 24, Issue 23
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
journal, October 2018
- Pádua, Ricardo A. P.; Sun, Yizhi; Marko, Ingrid
- Nature Communications, Vol. 9, Issue 1
Exploring the effect of N308D mutation on protein tyrosine phosphatase‐2 cause gain‐of‐function activity by a molecular dynamics study
journal, October 2018
- Sun, Ying‐Zhan; Chen, Xiu‐Bo; Wang, Rui‐Rui
- Journal of Cellular Biochemistry, Vol. 120, Issue 4
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
journal, October 2018
- LaRochelle, Jonathan R.; Fodor, Michelle; Vemulapalli, Vidyasiri
- Nature Communications, Vol. 9, Issue 1
Synthesis, activity evaluation, and pro-apoptotic properties of novel 1,2,4-triazol-3-amine derivatives as potent anti-lung cancer agents
text, January 2019
- Sun, Xian-Yu; Zhong, Chun-Yan; Qiu, Qing-Qing
- Taylor & Francis
Synthesis, activity evaluation, and pro-apoptotic properties of novel 1,2,4-triazol-3-amine derivatives as potent anti-lung cancer agents
text, January 2019
- Sun, Xian-Yu; Zhong, Chun-Yan; Qiu, Qing-Qing
- Taylor & Francis
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
journal, October 2018
- Pádua, Ricardo A. P.; Sun, Yizhi; Marko, Ingrid
- Nature Communications, Vol. 9, Issue 1
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
journal, October 2018
- LaRochelle, Jonathan R.; Fodor, Michelle; Vemulapalli, Vidyasiri
- Nature Communications, Vol. 9, Issue 1
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
journal, January 2020
- Lu, Hengyu; Liu, Chen; Huynh, Hung
- Oncotarget, Vol. 11, Issue 3
Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2
journal, December 2018
- Kostrzewa, Tomasz; Sahu, Kamlesh K.; Gorska-Ponikowska, Magdalena
- Drug Design, Development and Therapy, Vol. Volume 12
Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity
journal, November 2019
- Sitaram,
- International Journal of Molecular Sciences, Vol. 20, Issue 23
Design, Synthesis, and In Vitro Activity of Pyrazine Compounds
journal, December 2019
- Parsonidis, Panagiotis; Shaik, Mahammad; Serafeim, Athanasia Panagiota
- Molecules, Vol. 24, Issue 23
Synthesis, activity evaluation, and pro-apoptotic properties of novel 1,2,4-triazol-3-amine derivatives as potent anti-lung cancer agents
text, January 2019
- Sun, Xian-Yu; Zhong, Chun-Yan; Qiu, Qing-Qing
- Taylor & Francis
Figures / Tables found in this record: